Executive Insights Biosimilars in China: The Next Frontier

Xin Tao co-authored "Executive Insights Biosimilars in China: The Next Frontier" with professionals from IDG Capital and The WhiteOak Group.

They discuss the Chinese biosimilar market and project it will enjoy tremendous growth over the next five to 10 years due to rapidly increasing demand, more structured and comprehensive regulations, and a closing technology gap.

Read More: Executive Insights Biosimilars in China: The Next Frontier


Download PDF Back To Listing
Loading data